Patents by Inventor David Hagerty

David Hagerty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule
    Patent number: 10052360
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20160158318
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 9, 2016
    Inventors: Robert COHEN, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating scleroderma by administering a soluble CTLA4 molecule
    Patent number: 9296808
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: March 29, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20140286948
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 25, 2014
    Inventors: Robert COHEN, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule
    Patent number: 8722632
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule
    Patent number: 8703718
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING JUVENILE RHUMATOID ARTHRITIS BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20130251713
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: ROBERT COHEN, SUZETTE BELDER-CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
  • METHODS FOR TREATING SJOGRENS SYNDROME BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20130230518
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 5, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: ROBERT COHEN, SUZETTE BELDER-CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
  • Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule
    Patent number: 8497247
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 30, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20120258094
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 24, 2012
    Publication date: October 11, 2012
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
    Patent number: 8227420
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: July 24, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Method for treating a rheumatic disease using a soluble TLA4 molecule
    Patent number: 8148332
    Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE TLA4 MOLECULE
    Publication number: 20110311529
    Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: July 27, 2011
    Publication date: December 22, 2011
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING AN AUTOIMMUNE DISEASE USING A SOLUBLE CTLA4 MOLECULE AND A DMARD OR NSAID
    Publication number: 20100166756
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Application
    Filed: March 9, 2010
    Publication date: July 1, 2010
    Inventors: ROBERT COHEN, SUZETTE CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Publication number: 20100041602
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Application
    Filed: November 19, 2008
    Publication date: February 18, 2010
    Inventors: David Hagerty, James Rusnak
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Patent number: 7482327
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: January 27, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Hagerty, James Rusnak
  • Methods for treating immune system diseases using a soluble CTLA4 molecule
    Patent number: 7455835
    Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Robert James Peach, David Hagerty, Suzette Carr, Jean-Claude Becker, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
    Publication number: 20070009511
    Abstract: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
    Type: Application
    Filed: April 6, 2006
    Publication date: January 11, 2007
    Inventors: David Hagerty, James Rusnak
  • Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
    Publication number: 20040022787
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Application
    Filed: April 18, 2003
    Publication date: February 5, 2004
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker
  • Methods for treating rheumatic diseases using a soluble CTLA4 molecule
    Publication number: 20030083246
    Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: July 2, 2001
    Publication date: May 1, 2003
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker